Yale Medicine School: Study from Yale Cancer Biologists Identifies Chromatin Regulator WDR5 as Possible Drug Target in Triple-Negative Breast Cancer
September 01, 2022
September 01, 2022
NEW HAVEN, Connecticut, Sept. 1 (TNSjou) -- Yale School of Medicine issued the following news:
A new study from Yale Cancer Center scientists has identified the chromatin regulator WDR5 as a possible new drug target in triple negative breast cancer. The research was published online in eLife.
Researchers used anin vivogenetic screen to identify the gene WDR5 as an actionable epigenetic regulator required for metastatic progression in models of triple negative breast can . . .
A new study from Yale Cancer Center scientists has identified the chromatin regulator WDR5 as a possible new drug target in triple negative breast cancer. The research was published online in eLife.
Researchers used anin vivogenetic screen to identify the gene WDR5 as an actionable epigenetic regulator required for metastatic progression in models of triple negative breast can . . .